In a report published Wednesday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Health Management Associates HMA, and raised the price target from $14.50 to $20.00.
In the report, Jefferies noted, “We continue to have a positive view on HMA shares despite the stock's recent run given our belief that the strategic review being undertaken by mgmt will most likely result in the eventual sale of the company. Consistent with yesterday's media reports, we believe hospital providers CYH and HCA are both interested in evaluating an acquisition of HMA. At current levels, we believe HMA's risk-reward is compelling. Raising PT to $20.”
Health Management Associates closed on Tuesday at $16.75.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
